Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study

BACKGROUND: Data pertaining to biologic agents used for treating psoriasis in real-world settings are lacking at present. To compare drug survival at 52 weeks for a range of biologics used to treat psoriasis under real-world conditions. METHODS: This was a retrospective, single-center, observational...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ying, Lu, Jia-Jing, Zhong, Xiao-Yuan, Yu, Ying-Yuan, Yu, Ning, Wang, Yu, Yi, Xue-Mei, Ding, Yang-Feng, Shi, Yu-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592732/
https://www.ncbi.nlm.nih.gov/pubmed/36304759
http://dx.doi.org/10.2147/CCID.S387759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592732/
https://www.ncbi.nlm.nih.gov/pubmed/36304759
http://dx.doi.org/10.2147/CCID.S387759

Ejemplares similares